DNMT1 and acute myeloid leukemia: The consistency and predictability of metabolic reconfiguration enabled anticipation, out-maneuvering and even exploitation: simple, practical treatment modifications preserved the favorable therapeutic index of noncytotoxic DNMT1-depletion and markedly improved efficacy in preclinical in vivo models of aggressive chemo-refractory AML.